Mid-Phase III Meetings Suggested As Way To Increase First-Cycle Approvals

FDA should consider conducting mid-Phase III meetings with drug sponsors as a way to improve the likelihood of approving an application during the first review cycle, a report by Booz Allen Hamilton recommends